HD1

Sinclair A, Babbs CF, Griffin DD and Ash SR. Roux-Y intestinal bypass for administration of sorbents in uremia. Kidney Int Suppl 13(88):S153-S159, 1978.

HD2

Sinclair A, Griffin DD, Voreis and Ash SR. Sorbent binding of urea and creatinine in a Roux-Y intestinal segment. Clin Nephrol 11(2):97-104, 1979.

HD3

Ash SR, Barile RG, Thornhill JA, Sherman JD, and Wang N-HL. In vivo evaluation of calcium-loaded zeolites and urease for urea removal in hemodialysis. Trans Am Soc Artif Inter Organs 26:111-115, 1980.

HD4

Wang N-HL, Kessler DP and Ash SR. Mass transfer characteristics of a sorbent-based reciprocating dialyzer. Chem. Eng. Commun 5(5):347-365, 1980.

HD5

Ash SR, Barile RG, Wilcox PG, Wright DL, Thornhill JA, Dhein CR, Kessler DP, and Wang N-HL. The sorbent suspension reciprocating dialyzer: a device with minimal sorbent saturation. ASAIO J 4(1):28-40, 1981.

HD6

Barile RG, Wang N-HL, Blake DE, Belcastro PF, Gupta S, Regnier FE, Thornhill JA, Kessler DP, and Ash SR. A reciprocating, single-needle hemodialyzer with bidirectional flow of sorbent suspension. Artif Organs 6(3):267-279, 1982.

HD7

Badylak S, Ash SR, Thornhill JA, Carr DJ. Doppler ultrasonic detection of particulate release during hemodialysis with cellulose hollow-fiber and sorbent suspension reciprocating dialyzers. Artif Organs 8(2):220-223, 1984.

HD8

Davidson GW, Ash SR, et al. Assessment of biomaterials as components of a reciprocating dialyser during canine dialysis. Biomaterials 5(4):227-233, 1984.

HD9

Ash SR, Barile RG, Wilcox PG, Wright DL, Thornhill JA, Dhein CR, Kessler DP and Wang N-HL. The sorbent suspension reciprocating dialyzer: a device with minimal sorbent saturation. ASAIO J 4:28-40, 1984.

HD10

Winchester JF and Ash SR. Hemoperfusion for uremia: past, present, future. Kidney Int Suppl 17:S127-S130, 1985.

HD11

Ash RS, Carr DJ, Baker K, Schultz TW and Reynolds LO. Automatic priming, blood flow control, and rinsing during single access hemodialysis. Trans Am Soc Artif Inter Organs 31:499-503, 1985.

HD12

Ash SR, Carr DJ, and Blake DE. Sorbent chemicals in hemodialysis and medicine. Proc Materials Research Society on Biomedical Materials Boston, 1987.

HD13

Ash SR, Baker K, Blake DE, Carr DJ, Echard TG, Sweeney KD, Handt AE and Wimberly AL. Clinical trials of the BioLogic-HT - automated single access sorbent-based dialysis. ASAIO Trans 33(3):524-531, 1987.

HD14

Ash SR, Blake DE, Carr DJ, Baker K and Echard TG, The BioLogic-HD: hemodialysis simplified. Proc Intl Symposium Artif Organs pp. 263-277, 1986.

HD15

Koszuta JJ, Carter JM and Ash SR. Effect of ethanol perfusion on creatinine removal in a Roux-Y intestinal segment. Intl J Artif Organs 14(7):417-423, 1991.

HD16

Ash, SR. The Allient™ Dialysis System. Seminars in Dialysis, 2004 17(2):164-5.

HD17

Rosenbaum BP, Ash SR, Carr DJ. Predicting dialysate sodium composition in kidney dialysis using single point and multiple-dilution conductivity measurement. Submitted to ASAIO Journal 5/05, with positive reviews.

SHD-A0

Ash SR, Carr DJ, Blake DE, Truitt RB. Simpler, safer, more automated equipment for night-time home hemodialysis. PDI 19; Suppl 1: S87, 1999.

SHD-A1

Ash SR, Carr DJ, Harker KD, Truitt RB, Korkor AB. Simple, safe, single-lumen system for long duration dialysis. Blood Purif 18:74, 2000.

SHD-A2

Ash SR, Carr DJ, Harker KD, Truitt RB, Korkor AB. Simpler, safer, more-automated equipment for nighttime home hemodialysis. PDI 20 (Suppl 1):S101, 2000.

SHD-A3

Ash SR, Carr DJ, Harker K, Truitt RB, Korkor A. Every-other night hemodialysis (QOHD) with plate dialyzer as blood pump and single-lumen access. ASAIO J 46:223, 2000.

SHD-A4

Ash SR, Carr DJ, Harker K, Truitt RB, Korkor AB. Every-other night hemodialysis with single-lumen access, plate dialyzer as blood pump, and sorbent column (SHD). Int J Artif Organs 32:575, 2000.

SHD-R1

Kjellstrand CF. Interview with an expert: Daily home hemodialysis: Is longer, more frequent dialysis a ‘sleeping beauty’ waiting to awaken? Nephrology Incite, Summer 2000.

SHD-R2

Roberts M. Conference Report. 20th annual conference on peritoneal dialysis; 6th international symposium on home hemodialysis. Dialysis & Transplantation 29:555-558, 2000.

DT-L1

Ash SR. Treatment of acute hepatic failure with encephalopathy: a review. Int J Artif Organs 14(4):191-195, 1991.

DT-L2

Ash SR, Blake DE, Carr DJ, Carter C, Howard T, Makowka L. Neurologic improvement of patients with hepatic failure and coma during sorbent suspension dialysis. ASAIO Trans 37(3):M332-M334, 1991.

DT-L3

Ash SR, Blake DE, Carr DJ, Carter C, Howard T and Makowka L. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 15(3):151-161, 1992.

DT-L4

Ash SR, Carr DJ, Blake DE, Rainier JB, Demetriou AA, Rozga J. Effect of sorbent-based dialytic therapy with the Biologic-DT on an experimental model of hepatic failure. ASAIO J 39(3):M675-M680, 1993.

DT-L5

Ash SR, Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif Organs 18(5):355-362,1994.

DT-L6

Ash SR, Hemodiabsorption in the treatment of acute hepatic failure. ASAIO J 40(1):80-82, 1994.

DT-L7

Wilkinson AH, Ash SR, Nissenson AR. Hemodiabsorption in treatment of hepatic failure. Journal of Transplant Coordination 8:43-50, 1998.

DT-L8

Ash SR. Letter to the Editor. Artif Organs 22(6):518-519, 1998.

DT-L10

Ash SR. Overview of the treatment of fulminant hepatic failure. 2000 UpToDate, Burton Rose Editor.

DTL-A1

Ash SR, Wilkinson AH, Hughes RD, Williams R. BioLogic-DT System in treatment of acute hepatic coma; results of randomized prospective controlled trials. American Society for Artif Organs. 42(2)11, March-April 1996.

DTL-A2

Ash SR, Patzer JF, Carr DJ, Blake DE. Push-pull sorbent-based pheresis in treatment of acute hepatic failure with coma (AHF). Amer. Soc. for Artificial Internal Organs. 43(2):18, March-April 1997.

DTL-A3

Ash S, Wilkinson A, Hughes R, Williams R. BioLogic-DT system in treatment of acute hepatic coma; results of randomized, prospectively controlled trials. J Hepatology 25(1):101, 1996.

DTL-A4

Mazariegos GV, Ash SR, Patzer JF. Preliminary results: randomized clinical trial of the BioLogic-DT in treatment of acute hepatic failure (AHF) with coma. Artif Organs 21(6):529, 1997.

DTL-A5

Mazariegos GV, Kramer DK, Linden P, Pinna A, Fung JJ, Ash SR, Patzer JF. Treatment of hepatic failure with advanced encephalopathy using the BioLogic-DT: Preliminary clinical results. Critical Care Society, 1998.

DTL-A6

Ash SR, Leamon KD, Gingrich CH. Hemodiabsoption (The BioLogic-DT System) in treatment of hepatic failure with encephalopathy: Summary of randomized, prospectively controlled clinical trials. Hepatology 28(4, Pt. 2):497A, 1998.

DTL-A7

Ash SR, Kuczek T, Foster DE, Blake DE, Gingrich CH. Hemodiabsorption in treatment of hepatic failure: summary of randomized, prospectively controlled clinical trials with the BioLogic-DT System. ASAIO J 45:202, 1999. (Slide Presentation ASAIO `99.)

DTL-A8

Ash SR, Kuczek T, Foster DE, Blake DE, Gingrich CH, Mankus RA. Hemodiabsorption in treatment of hepatic and hepatorenal failure: summary of randomized, prospectively controlled clinical trial. J Am Soc Nephrol 10:628A, 1999.

DTL-A9

Ash SR, Kuczek T, Foster DE, Blake DE, Gingrich CH. Hemodiabsorption in treatment of hepato-renal failure: Summary of randomized, prospectively controlled clinical trials. Hepatology 30:169A, 1999.

DTL-A10

Ash SR, Kuczek T, Foster DE, Blake DE, Gingrich CH. Liver dialysis in treatment of hepatic failure and hepatorenal failure: Summary of randomized, prospectively controlled clinical trials. Blood Purif 18:67, 2000.

DTL-A11

Ash SR, Kuczek T, Blake DE, Gingrich CH. Liver dialysis in treatment of hepatorenal failure: randomized clinical trials and clinical experience. ASAIO J 46:223, 2000.

DTL-A12

Ash S, Kuczek T, Foster D, Steczko J, Blake D, Gingrich C. Liver dialysis in treatment of hepatic failure and hepatorenal failure: randomized clinical trials and recent improvements. Int J Artif Organs 23:534, 2000.

DTL-A13

Ash SR, Kuczek T, Steczko J, Blake DE, Gingrich CH. Randomized clinical trials of liver dialysis in treatment of hepatic failure and hepatorenal failure. J Am Soc Nephrol 11:173A, 2000.

DTL-A14

Ash SR, Blake DE, Carr DJ, Harker KD, Levy H. Push-pull sorbent-based pheresis and hemodiabsorption in treatment of hepatic failure: preliminary results of a clinical trial. Ther Apher 4:423, 2000. (Abstract #36)

DTL-A15

Ash SR, Kuczek T, Steczko J, Blake DE, Gingrich CH. Randomized clinical trials of liver dialysis in treatment of hepatic failure and hepatorenal failure. Ther Apher 4:421, 2000. (Abstract #27)

DT-R0

Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 17(12):657-662, 1994.

DT-R1

Kaplan AA, Epstein M. Extracorporeal blood purification in the management of patients with hepatic failure. Seminars in Neph 17(6):576-582, 1997.

DT-R2

Whitehead T, Beck D, Ramachandran R. Lowell J, Shenoy S, Howard T. Bioreactor for extracorporeal liver assist device (ELAD). ASAIO J 44(2):92A, 1998.

DT-R3

Whitehead TD, Lowell JA. Bioreactor for extracorporeal liver assist device for prolonged treatments. Hepatology 26(4):168A, 1997.

DT-R4

Ellis AJ, Hughes RB, Nicholl D, Langley PG, Wendon JA, O’Grady JG, Williams R. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT. Int J Artif Organs 22(1):27-34, 1999.

DT-R5

Kramer L, Gendo A, Madl C, Mullen K, Kaminski-Russ K, Zauner C, et al. A controlled study of the BioLogic-DT System in chronic hepatic encephalopathy. Hepatology 28(4, Pt. 2):401A, 1998.

DT-R6

Jeyaraj P. The bio-artificial liver. Liver Update ’99. Selangor, Malaysia. Pg. 28.

DT-R7

Kramer L, Gendo A, Madl C, Ferrara I, Funk G, Schenk P, Sunder-Plassmann G, Horl WH. Biocompatibility of a cuphrophane charcoal-based detoxifier device in cirrhotic patients with hepatic encephalopathy. Am J Kidney Dis 36:1193-2000, 2000.

DT-R8

Huang K-W, Ko W-J, Lee P-H, Lai M-Y. Improvement of hepatic encephalopathy following treatment of fulminant hepatic failure with extracorporeal blood detoxification. 3rd World Congress of International Society for Apheresis (ISFA). January 11-14, 2001, Taipei, Taiwan. Proceedings, Page 81.

DT-R9

Po W-J, Lee P-H, Lai M-Y. Outcome of Biological-DT treatment of patients with fulminant hepatic failure. 3rd World Congress of International Society for Apheresis (ISFA). January 11-14, 2001, Taipei, Taiwan. Proceedings, Page 47.

DT-R10

Kraus MA. Post-market experience of the HemoTherapies Unit™ for liver dialysis extracorporeal liver-support therapy. (6th International Conference on CRRT) Blood Purif 19:331; 2001.

DT-R11

Stribling R, Ghalib RH, Duchini A, Seu P, Goss JA. Improvement in respiratory status and quality of life after liver dialysis treatment of hepatic encephalopathy in critically ill cirrhotic patients. Hepatology 34:659A, 2001.

DT-R12

Stribling R, Ghalib RH, Duchini A, Seu P, Goss J. Reversal of stage 3 hepatic encephalopathy in therapy-resistant critically ill cirrhotic patient: the impact of liver dialysis with the HemoTherapies Unit. Hepatology 34:660A, 2001.

DT-R13

Stuart M. Liver Assist Devices: Proof of Life. Startup 7; 3: 19-28, 2002.

DT-R14

Hillebrand DJ, Hill K, Hu KQ, Cottrell A, Teichman S. Formal heparin anticoagulation protocol improves safety of charcoal-based liver assist treatments. ASAIO Journal 48;2: A 186, 2002

DT-R15

Falkenhagen D, Strobl W, Hartmann J, Schrefl A, Linsberger I, Kellner KH, Aussenegg F, Leitner A. Patient Safety Technology for microabsorbent systems in extracorporeal blood purification. Artificial Organs 26 (2): 84-90, 2002

DT-R16

Huang KW, Chao A, Chou NK, Ko WJ. Hepatic encephalopathy and cerebral blood flow improved by liver dialysis treatment. Int J of Artific Organs 26 (2): 149-151, 2003

DT-R17

Patzer JF. Bound Solute Dialysis. ASAIO Journal 49 (3): 271-281, 2003.

DT-R18

Davenport A. Extracorporeal support for patients with hepatic failure. Hemodialysis International  7(3): 256-263, 2003.

DT-R19

Hillebrand DJ, Hill KB, Hu KQ, Strutt M, Wilson B, Cottrell A, Teichman S, Hay K, Bull B. Formal heparin anticoagulation protocol improves safety of charcoal-based liver assist treatments. ASAIO J, pending 2003.

DT-R20

Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and Bioartificial support systems for acute and acute-on-chronic liver failure. JAMA 289(2); 2003, p 217-222.

DT-R21

Aladag M, Gurakar A, Jalil S, Wright H, Alamian S, Rashwan S, Sebastian A, Nour B. A liver transplant experience with Liver Dialysis in the management of patients with fulminant hepatic failure: a preliminary report. Transplantation Proceedings; 36, 2004.

DT-R22

Jones SKB (RN), When the liver fails. www.rnweb.com, Vol 66, No. 11, 32-36, November 2003

DT-R23

Akdodan M, El-Sahwi K, Ahmed U, Rashwan S, Sebastian A, Wright H, Nour B, Gurakar A. Experience with liver dialysis in acetaminophen induced fulminant hepatic failure; a preliminary report. Turkish Journal of Gastroenterology 2003, V 14, No 3, Page 164-167.

DT-R24

El-Sahwi K, Karim S, Akdodan M, Ahmed U, Monlux R, Rashwan S, Smith C, Wright H, Sebastian A, Nour B, Gurakar A.  The impact of total plasma exchange and/or liver dialysis on the management of acute hepatic encephalopathy. Gastroenterology 123: 2002, p55 (a) .

DT-R25

Hill K, Hu KQ, Cottrell A, Teichman S, Hillebrand DJ. Charcoal-based hemodiabsorption liver support for episodic type C hepatic encephalopathy. Am J of Gastroenterology 2003: 98(12); 2763-2770.

DT-R26

Hillebrand DJ, Hill K, Hu KQ, et al. Formal Heparin Anticoagulation Protocol Improves Safety of Charcoal-Based Liver Assist Treatments. ASAIOJ 2002;48:186

DT-D1

Shihab-Eldeen AA, Peck GE, Ash SR, Kaufman GM. Evaluation of the sorbent suspension reciprocating dialyser in the treatment of overdose of paracetamol and phenobarbitone. J Pharm Pharmacol 40:381-387, 1988.

DT-D2

Ash SR, Blake DE, Carr DJ. Increasing selectivity of chemical removal from blood by pre-loading charcoal of the BioLogic-DT. American Filtration Society 7:329-332, 1993

DT-D3

Ash SR, Blake DE, Carr DJ, Rainier JB, Gingrich CH, Truitt RB. Selective chemical removal from blood by a sorbent suspension dialysis system (Biologic-DT). American Filtration Society 7:325-328, 1993.

DT-D4

Ash SR, Levy H, Akmal M, Mankus RA, Sutton JM, Emery DR, Scanlon JC, Blake DE, Carr DJ. Treatment of severe tricyclic antidepressant overdose with extracorporeal sorbent detoxification. Advances in Renal Replacement Therapy 9:31-41, 2002.

DT-D5

Ash SR, Caldwell CA, Singer GG, Lowell JA, Howard TK, Rustgi VK. Treatment of acetaminophen-induced hepatitis and fulminant hepatic failure with extracorporeal sorbent-based devices. Advances in Renal Replacement Therapy 9:42-53, 2002.

DTD-A1

Ash SR, Rustgi VK. Recovery of hepatic function following treatment of acetaminophen overdose with the BioLogic-DT. Abstract #348, pg. A-88. Proceeding from Digestive Disease Week. May 1997.

DTD-A2

Lowell JA, Caldwell CA, Singer G, Rustgi VK, Ash SR, Wendon JA, Williams R. Treatment of acetaminophen-induced hepatotoxicity and fulminant hepatic failure by the BioLogic-DT® System. Hepatology 26:4(2):252A, 1997.

DTD-A3

Ash SR, Caldwell CA, Singer GG, Lowell JA, Howard TK, Rustgi VK, Hughes R, Ellis T, Wendon JA, Williams R. Treatment of acetaminophen-induced hepatitis and fulminant hepatic failure by the BioLogic-DT system. ASAIO J 45:204, 1999. (Poster presentation at ASAIO `99.)

DTD-A4

Mankus RA, Ash SR, Levy H, Akmal M, Blake DE, Carr DJ, Emery DR, Scanlon JC. Treatment of severe tricyclic antidepressant (TCA) overdose using hemodiabsorption by the BioLogic-DT system. ASAIO J 45:123, 1999. (Poster presentation at ASAIO `99.)

DTD-A5

Ash SR, Levy H, Akmal M, Mankus RA, Sutton JM, Emery DR, Scanlon JC, Blake DE, Carr DJ. Treatment of severe tricyclic antidepressant overdose with the BioLogic-DT System. J Am Soc Nephrol 10:628A, 1999.

DTD-A6

Ash SR, Caldwell CA, Singer GG, Lowell JA, Howard TK, Rustgi VK. Treatment of acetaminophen-induced hepatitis and fulminant hepatic failure by the BioLogic-DT System. Hepatology 30:552A, 1999.

PF-L1

Ash SR, Blake DE, Carr DJ, Harker KD. Push-pull sorbent-based pheresis for treatment of acute hepatic failure: The BioLogic-detoxifier/plasma filter System. ASAIO J 44(3):129-139, 1998.

PF-L2

Ash SR, Knab WR, Blake DE, Carr DJ, Steczko J, Harker KD, Levy H. Push-pull sorbent-based pheresis and hemodiabsorption in treatment of hepatic failure: preliminary results of a clinical trial with the BioLogic-DTPF System. Therapeutic Apheresis 4:218-228, 2000.

PF-L3

Steczko J, Bax KC, Ash SR. Effect of hemodiabsorption and sorbent-based pheresis on amino acid levels in hepatic failure. Int J Artificial Organs 6:375-388 2000.

PF-L4

Ash SR. Powdered Sorbent liver dialysis and pheresis in treatment of hepatic failure. Therapeutic Apheresis 5(5):404-416, 2001.

PF-L5

Ash SR. Extracorporeal blood detoxification by sorbents in treatment of hepatic encephalopathy. Advances in Renal Replacement Therapy 9:3-18, 2002.

PFL-A1

Ash SR, Carr DJ, Blake DE, Harker KD. Push-pull sorbent-suspension pheresis for treatment of acute hepatic failure: the BioLogic-DTPF. ASAIO J 42(2):11, 1996.

PFL-A2

Ash SR, Knab WR, Steczko J, Carr DJ, Blake DE. Hepatic failure treatment by powdered sorbent pheresis - the BioLogic-DTPF System. ASAIO J 44(2):92A, 1998.

PFL-A3

Ash SR, Knab WR, Blake DE, Carr DJ, Harker DK, Levy H. The BioLogic-DTPF System in treatment of fulminant hepatic failure: preliminary results of a clinical trial. Hepatology 28(4, Pt. 2):496A, 1998.

PFL-A4

Ash SR, Blake DE, Carr DJ, Harker KD, Levy H. Push-pull sorbent-based pheresis (BioLogic-DTPF) in treatment of hepatic failure: preliminary results of a clinical trial. ASAIO J 45:203, 1999. (Poster presentation at ASAIO `99).

PFL-A5

Steczko J, Ash SR, Bax KC, Blake DE. Amino acid profiles during hepatic failure during sorbent-based dialysis and sorbent-based pheresis treatment. Presented at 10th International Symposium on Hepatic Encephalopathy and Nitrogen Metabolism, Turkey, 1999.

PFL-A6

Ash SR, Blake DE, Carr DJ, Harker KD, Levy H. Push-pull sorbent-based pheresis (BioLogic-DTPF System) in treatment of hepatic failure: preliminary results of a clinical trial. Presented at for 10th International Symposium on Hepatic Encephalopathy and Nitrogen Metabolism, Turkey, 1999.

PFL-A7

Ash SR, Blake DE, Carr DJ, Harker KD, Levy H. Push-pull sorbent-based pheresis (BioLogic-DTPF System) in treatment of hepatic failure: preliminary results of a clinical trial. Therapeutic Apheresis 3(2):113, 1999.

PFL-A8

Ash SR, Bax KC, Steczko J. Changes in plasma amino acid levels in hepatic failure patients during sorbent-based dialysis and sorbent-based pheresis treatment. Hepatology 30:675A, 1999.

PFL-A9

Ash SR, Blake DE, Carr DJ, Harker KD, Levy H. Push-pull sorbent-based pheresis and hemodiabsorption in treatment of hepatic failure: preliminary results of a clinical trial. 3rd World Congress of International Society for Apheresis (ISFA). January 11-14, 2001, Taipei, Taiwan. Proceedings, Page 48.

PFL-R1

Whitehead TD, Lowell JA, Mohanakumar T, Beck DJ, Ramachandran PA, Shenoy S, Howard TK. Bioreactor for extracorporeal liver assist device for prolonged treatments. Hepatology 26(4):168A, 1997.

PF-S1

Levy H, Ash SR, Knab WR, Steczko J, Carr DJ, Blake DE. Systemic inflammatory response syndrome (SIRS) treatment by powdered sorbent pheresis: the BioLogic-Detoxification Plasma Filtration System. ASAIO J 44(5):M659-M665, 1998.

PF-S2

Steczko J, Ash SR, Blake DE, Carr DJ, Bosley RH. Cytokines and endotoxin removal by sorbents and its application in push-pull sorbent-based pheresis: The BioLogic-DTPF System. Artif Organs 23:310-318, 1999.

PF-S3

Ash SR, Steczko J, Levy H, Blake DE, Carr DJ. Treatment of systemic inflammatory response syndrome by push-pull powdered sorbent pheresis: A Phase I clinical trial. Therapeutic Apheresis 5 (6):497-505, 2001

PF-S4

Peter AT, Ash SR, Steczko J, Turek JJ, Blake DE, Carr DJ, Knab WR, Bosley RH. Push-pull sorbent-based pheresis treatment in an experimental canine endotoxemia model: preliminary report. Intern J Artif Organs 22:177-188, 1999.

PFS-A1

Steczko J, Ash SR, Carr DJ, Blake DE. Cytokine removal from plasma by push-pull sorbent-based pheresis (the BioLogic-DTPF System). ASAIO J 43(2):82, 1997.

PFS-A2

Ash SR, Steczko J, Carr DJ, Blake DE. Cytokine, endotoxin, and bilirubin removal from plasma by push-pull sorbent-based pheresis (the BioLogic DTPF System). Artif Organs 21(6):499, 1997.

PFS-A3

Ash SR, Steczko J, Carr DJ, Blake DE. Cytokine and bilirubin removal in acute hepatic failure by push-pull sorbent-based pheresis (the BioLogic-DTPF System). Hepatology 26(4p2):475A, 1997.

PFS-A4

Steczko J, Ash SR, Levy H, Carr DJ, Blake DE. Cytokine removal from plasma of patients with sepsis by the BioLogic-DTPF System. Hepatology 26:4(2):604A, 1997.

PFS-A5

Levy H, Ash SR, Knab WR, Steczko J, Carr DJ, Blake DE. Systemic inflammatory response syndrome (SIRS) treatment by powdered sorbent pheresis: the BioLogic-DTPF System. ASAIO J 44(2):81A, 1998.

PFS-A6

Levy H, Ash SR, Steczko J, Carr DJ. Cytokine removal from plasma of patients with SIRS by the BioLogic-DTPF. Poster presentation at 18th International Symposium. Critical Care 2(1), March 1998.

PFS-A7

Ash SR, Levy H, Mankus RA, Knab WR, Steczko J, Carr DJ, Blake DE. Treatment of systemic inflammatory response syndrome (SIRS) by powdered sorbent pheresis: the BioLogic-DTPF System. J Am Soc Nephrol 9:471A, 1998.

PFS-A8

Levy H, Ash SR, Knab WR, Steczko J, Carr DJ, Blake DE. Treatment of systemic inflammatory response syndrome (SIRS) by powdered sorbent pheresis: the BioLogic-DTPF System. Hepatology 28(4, Pt.2):225A, 1998.

PFS-A8

Ash SR, Levy H, Steczko J, Carr DJ, Blake DE. Push-pull sorbent-based pheresis (BioLogic-DTPF System) in treatment of systemic inflammatory response syndrome (SIRS). Therapeutic Apheresis 3(2):113, 1999.

PFS-A9

Ash SR, Levy H, Steczko J, Carr DJ, Blake DE. Push-pull sorbent-based pheresis and liver dialysis in treatment of SIRS (Inflammatory Response Syndrome) 3rd World Congress of International Society for Apheresis (ISFA). January 11-14, 2001, Taipei, Taiwan. Proceedings, Page 102.

HT-1

Steinhart CR, Ash SR, Gingrich C, Sapir D, Keeling GN, Yatvin MB. Effect of whole body hyperthermia on AIDS patients with Kaposi’s sarcoma: a pilot study. J Acquired Deficiency Syndromes and Human Retrovirology 11(3):271-281, 1996.

HT-2

Ash SR, Steinhart CR, Curfman MF, et al. Extracorporeal whole body hyperthermia treatments for HIV infection and AIDS. ASAIO J 43(5):M830-M838, 1997.

HT-A1

Ash SR, Steinhart CR, Curfman MF, Gingrich CH, Sapir DA, Yatvin MB. Whole body hyperthermia treatments for AIDS; a randomized, controlled trial. American Society for Artif Organs 42(2):98, 1996.

HT-A2

Yatvin MB, Shenoy M, Li W, Steinhart C, Ash SR, Gingrich C, Sapir D, Keeling, G. Whole-body hyperthermia to treat HIV-infection. 5th Annual AIDS Day Conference, Munich, Germany, January 1996.

HT-A3

Ash SR, Steinhart CR, Curfman MF, Gingrich CH, Sapir DA, Yatvin MB. Whole body hyperthermia treatments for AIDS; combination with protease inhibitor therapy. Amer. Soc. for Artificial Internal Organs. 43(2):34, 1997.

HT-A4

Ash S, Steinhart C, Curfman M, Gingrich C, Sapir D, Yatvin M. Whole body hyperthermia treatment (WBHT) for AIDS: a randomized, controlled study in patients with drug treatment failure. Artif Organs 21(6):567, 1997.

HT-R1

Zwischenberger JB, Woodson L, Vertrees RA, Bidell E, Deyo DJ, Chernin J, Graves D, Bidani A. Perfusion-induced systemic hyperthermia for advanced non-small cell lung cancer: initial clinical experience. Abstract submitted for AACR Annual Meeting, 1999.

HT-R2

Zwischenberger JB, Vertrees RA, Woodson LC, Bedell EA, Alpard SK, McQuitty C, Chernin JM. Percutaneous veno-venous perfusion-induce4d systemic hyperthermia for advanced non-small cell lung cancer: initial clinical experience. Pending publication, presented at American Association for Cancer research, 4/99, Philadelphia, PA.